Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARDS Stock Summary
- With a market capitalization of $16,643,840, ARIDIS PHARMACEUTICALS INC has a greater market value than merely 5.28% of US stocks.
- ARDS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.57% of US stocks.
- Revenue growth over the past 12 months for ARIDIS PHARMACEUTICALS INC comes in at 422.81%, a number that bests 97.54% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ARIDIS PHARMACEUTICALS INC, a group of peers worth examining would be TMDI, TCRX, GRNA, SYBX, and PIRS.
- ARDS's SEC filings can be seen here. And to visit ARIDIS PHARMACEUTICALS INC's official web site, go to www.aridispharma.com.
ARDS Valuation Summary
- ARDS's price/sales ratio is 8.6; this is 319.51% higher than that of the median Healthcare stock.
- ARDS's EV/EBIT ratio has moved up 3.2 over the prior 54 months.
Below are key valuation metrics over time for ARDS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARDS | 2023-01-20 | 8.6 | -0.7 | -0.7 | -1.1 |
| ARDS | 2023-01-19 | 9.3 | -0.7 | -0.8 | -1.2 |
| ARDS | 2023-01-18 | 9.1 | -0.7 | -0.8 | -1.2 |
| ARDS | 2023-01-17 | 9.4 | -0.8 | -0.8 | -1.2 |
| ARDS | 2023-01-13 | 9.2 | -0.7 | -0.8 | -1.2 |
| ARDS | 2023-01-12 | 9.1 | -0.7 | -0.8 | -1.2 |
ARDS Price Target
For more insight on analysts targets of ARDS, see our ARDS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $18.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ARDS Stock Price Chart Interactive Chart >
ARDS Price/Volume Stats
| Current price | $0.68 | 52-week high | $2.94 |
| Prev. close | $0.71 | 52-week low | $0.57 |
| Day low | $0.60 | Volume | 1,678,800 |
| Day high | $0.70 | Avg. volume | 2,480,990 |
| 50-day MA | $1.05 | Dividend yield | N/A |
| 200-day MA | $1.24 | Market Cap | 14.15M |
Aridis Pharmaceuticals Inc. (ARDS) Company Bio
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.
Latest ARDS News From Around the Web
Below are the latest news stories about ARIDIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARDS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). AR-301-002, the first of two planned Phase 3 studies, enrolled |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! |
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateAR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infectiv |
ARDS Price Returns
| 1-mo | -42.37% |
| 3-mo | -29.53% |
| 6-mo | -69.09% |
| 1-year | -62.43% |
| 3-year | -90.16% |
| 5-year | N/A |
| YTD | -42.37% |
| 2022 | -49.36% |
| 2021 | -61.61% |
| 2020 | 36.40% |
| 2019 | -59.87% |
| 2018 | N/A |
Continue Researching ARDS
Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...